Asieris(SH:688176)2025-04-29 13:28Revenue Performance - The company's revenue for Q1 2025 reached ¥61,101,125.72, representing a 151.24% increase compared to ¥24,319,537.45 in the same period last year[4] - Total revenue for Q1 2025 reached RMB 61,101,125.72, a significant increase from RMB 24,319,537.45 in Q1 2024, representing a growth of approximately 151.5%[16] - Total operating revenue for Q1 2025 was 61,061,157.83 RMB, significantly up from 26,465,560.01 RMB in Q1 2024, representing an increase of about 130.8%[20] - The company attributed the revenue increase primarily to higher sales volumes of Pazopanib tablets and Nilotinib tablets during the reporting period[6] Profitability - The net profit attributable to shareholders was -¥83,530,738.28, slightly worse than -¥82,848,207.86 in the previous year[4] - In Q1 2025, the company reported a net profit of -86,341,679.22 RMB, compared to -82,969,385.29 RMB in Q1 2024, indicating a year-over-year decline of approximately 4.1%[17] - The company’s total comprehensive income for Q1 2025 was -86,393,882.94 RMB, compared to -84,084,642.90 RMB in Q1 2024, reflecting a decline of about 2.7%[18] - The basic earnings per share remained at -¥0.15, unchanged from the previous year[4] - The basic earnings per share for Q1 2025 remained at -0.15 RMB, consistent with Q1 2024[18] Research and Development - R&D expenses totaled ¥55,061,232.76, a decrease of 19.15% from ¥68,099,878.30 year-on-year, with R&D expenses accounting for 90.11% of revenue[4] - Research and development expenses for Q1 2025 were 55,061,232.76 RMB, down from 68,099,878.30 RMB in Q1 2024, indicating a reduction of approximately 19.1%[17] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥110,357,157.61, an improvement from -¥129,110,035.08 in the same period last year[4] - The company's operating cash flow for Q1 2025 was -110,357,157.61 RMB, an improvement from -129,110,035.08 RMB in Q1 2024[21] - Cash and cash equivalents as of March 31, 2025, amounted to RMB 871,264,190.39, up from RMB 628,197,162.91 as of December 31, 2024, reflecting a growth of approximately 38.7%[12] - Cash and cash equivalents at the end of Q1 2025 totaled 865,579,055.99 RMB, an increase from 775,167,766.25 RMB at the end of Q1 2024[21] Assets and Liabilities - The company's total assets decreased by 2.76% to ¥2,161,563,230.97 from ¥2,222,991,903.79 at the end of the previous year[5] - Total assets decreased to RMB 2,161,563,230.97 as of March 31, 2025, from RMB 2,222,991,903.79 at the end of 2024, a decline of about 2.8%[14] - The equity attributable to shareholders decreased by 3.99% to ¥1,890,799,054.31 from ¥1,969,405,336.09 at the end of the previous year[5] - The company's equity attributable to shareholders decreased to RMB 1,890,799,054.31 as of March 31, 2025, from RMB 1,969,405,336.09 at the end of 2024, a decline of about 4.0%[14] - Total liabilities increased to RMB 272,307,481.81 as of March 31, 2025, compared to RMB 252,618,105.29 at the end of 2024, indicating an increase of approximately 7.8%[14] Other Financial Metrics - The company reported a total of ¥5,821,474.77 in non-recurring gains and losses for the period[6] - The company held 8,667,675 shares in its repurchase account, accounting for 1.52% of total shares as of the reporting period[10] - The company did not report any changes in the participation of major shareholders in the securities lending business[11] - The company reported a tax expense of -49,563.51 RMB in Q1 2025, compared to -343,675.93 RMB in Q1 2024, indicating a reduction in tax liabilities[17] - Investment activities generated a net cash flow of 319,563,507.59 RMB in Q1 2025, compared to 554,416,433.51 RMB in Q1 2024, showing a decrease of approximately 42.4%[21]